Cerevel Therapeutics Holdings, Inc. (CERE)

NASDAQ: CERE · IEX Real-Time Price · USD

42.55

-0.04 (-0.09%)

At close: May 3, 2024, 4:00 PM

42.61

+0.06 (0.15%)

After-hours: May 3, 2024, 5:47 PM EDT

CERE Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-432.84	-351.51	-225.33	-148.27	-128.39
Depreciation & Amortization	5.63	4.9	2.73	0.4	0.18
Share-Based Compensation	69.41	38.78	23.94	10.52	8.31
Other Operating Activities	15.5	14.64	20.12	23.42	49.18
Operating Cash Flow	-342.3	-293.19	-178.55	-117.8	-70.72
Capital Expenditures	-3.81	-3.95	-10.5	-18.89	-1.1
Change in Investments	77.53	-384.88	-425.16	0	0
Investing Cash Flow	73.72	-388.83	-435.66	-18.89	-1.1
Share Issuance / Repurchase	517.51	251.32	337.1	442.62	60.06
Debt Issued / Paid	31.25	372.27	31.25	0	0
Other Financing Activities	-0.14	-0.4	55.25	-1.78	-
Financing Cash Flow	548.62	623.19	423.6	440.84	60.06
Net Cash Flow	280.04	-58.83	-190.61	304.14	-11.76
Free Cash Flow	-346.11	-297.14	-189.05	-136.69	-71.82
Free Cash Flow Per Share	-2.14	-1.96	-1.38	-1.86	-1.63

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).